Article Versions Notes

Miteva D, Kitanova M, Batselova H, Lazova S, Chervenkov L, Peshevska-Sekulovska M, Sekulovski M, Gulinac M, Vasilev GV, Tomov L, et al. The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice. Vaccines. 2023; 11(7):1181. https://doi.org/10.3390/vaccines11071181

Miteva, Dimitrina, Meglena Kitanova, Hristiana Batselova, Snezhina Lazova, Lyubomir Chervenkov, Monika Peshevska-Sekulovska, Metodija Sekulovski, Milena Gulinac, Georgi V. Vasilev, Luchesar Tomov, and et al. 2023. "The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice" Vaccines 11, no. 7: 1181. https://doi.org/10.3390/vaccines11071181

Miteva, D., Kitanova, M., Batselova, H., Lazova, S., Chervenkov, L., Peshevska-Sekulovska, M., Sekulovski, M., Gulinac, M., Vasilev, G. V., Tomov, L., & Velikova, T. (2023). The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice. Vaccines, 11(7), 1181. https://doi.org/10.3390/vaccines11071181